A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery

Parlay Wellness · ClinicalTrials.gov registration

Primary endpoints are change in hs-CRP and IL-6 at week 8 plus self-reported swelling. Registry checked 2026-08-15: completed November 2025, first posted 2026-08-07, no results posted. A manufacturer-run, uncontrolled study of an oral consumer product.

Population

Physically active adults, United States

Intervention

Two BPC-157 gummies daily (500 µg per serving) for 8 weeks

Comparator

None — single-arm, unblinded

Limitations

Single-arm and unblinded on inflammatory markers that move with training alone; sponsor sells the product; registered nine months after it finished, with no results.